The biological and clinical significance of the ER-/PR+ breast cancer subtype is even more controversial, with some reports claiming it represents a distinct, clinically useful biologic entity [15,16], while others posit that ER-/PR+ classification is primarily a technical artifact [17,18] and too rare to be of clinical use [2]. This evidence concerns the gene PGR and breast carcinoma.